Preliminary Phase I data clarified that BNZ-1 was well tolerated and inhibited IL-2 and IL-15 activity, leading to clinical improvement in participants with cutaneous T-cell lymphoma (CTCL) by rejuvenating anti-lymphoma immunity and reducing inflammatory responses (NCT03239392) (93). Here, IL15 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.